LY3962673

N/A

Report date: 2025/06/06 20:01:13
NME

Base Information

Drug NameLY3962673
Drug Alias NameLY3962673LY-3962673
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKRAS G12D inhibitors
TargetsKRAS G12D
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsCarcinoma, Pancreatic Ductal +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesItaly +[9] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsCarcinoma, Pancreatic Ductal
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A